Research & Academia
Breakthroughs, publications and the frontier of discovery.
Latest Research & Academia news
The NIH funding crisis that could reshape biotech for years to come
Read at Drug Discovery News →Long-Lived Skin Models: Outer Bio Keeps Human Skin Viable for Over Four Weeks
Read at trendhunter.com →Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
Read at 01net →Novo Nordisk Taps Anthropic’s Claude to Speed Drug Discovery
Read at Unite.AI →Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
Read at biospace.com →From the knowledge base
Trialynx Wins DPHARM Idol Disrupt 2026
Trialynx takes home the DPHARM Idol Disrupt award from the 2026 DPHARM conference.
Cellares links with GenomeFrontier to test automation approach for virus-free CAR-Ts
Cellares is partnering with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the integrated contract developer and manufacturer’s cell shuttle platform for use in the production of virus-free CAR-T therapies.
Vera’s strong phase 3 IgAN data for Trutakna intensify kidney disease rivalry
New phase 3 data show Vera Therapeutics’ Trutakna successfully stabilizes kidney function in IgA nephropathy patients, mirroring an earlier clinical success from Otsuka’s Voyxact and heating up competition in a rapidly evolving market race.
AZ, Daiichi's Enhertu scores long-awaited NICE blessing in HER2-low breast cancer
After a 2024 rebuff, AstraZeneca and Daiichi Sankyo’s star antibody drug conjugate Enhertu has been deemed cost effective for NHS use in HER2-low advanced breast cancer by England and Wales' drug value assessor.
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through a phase 3 trial and hopefully on to commercialization.
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.